Thelansis

  Resistant hypertension (RH) is characterized by persistently elevated blood pressure (BP) despite the concurrent administration of three antihypertensive drug classes. These typically include a long-acting calcium channel blocker, a renin-angiotensin system blocker (either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker), and a diuretic. Additionally, RH encompasses cases where BP reaches target values despite the use of four or more antihypertensive medications. Diagnosis necessitates confirmation of medication adherence and the exclusion of the "white-coat effect," where office BP surpasses the goal but out-of-office BP remains within the target range. Patients with RH face elevated risks of various adverse outcomes. Specifically, they exhibit a 32% heightened risk of developing end-stage renal disease, a 24% increased risk of experiencing an ischemic heart event, a 46% higher likelihood of heart failure, a 14% elevated risk of stroke, and a 6...